Floatz logo

Autologous Bcma/Cd19 Dual-Target Car-T Module

Relapsed/Refractory Multiple Myeloma or Plasma Cell Leukemia

Beijing BiotechCell therapyPhase 1/2Active
CC
47/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
33/ 100
Competitive Position
89/ 100

Competitive context

497 Active assets in the Relapsed/Refractory Multiple Myeloma or Plasma Cell Leukemia cohort.

Asset / SponsorPhaseRating
FILGRASTIM
Jonsson Comprehensive Cancer Center
Phase 4BBB
Inno-206
University of Arkansas
Phase 3BBB
Hyaluronidase fihj
Massachusetts General Hospital
Phase 4BBB
Busulphan
M.D. Anderson Cancer Center
Phase 4BBB
Filanesib
PETHEMA Foundation
Phase 2BBB

View all 50 →

Same molecule, other indications

Autologous Bcma/Cd19 Dual-Target Car-T Module is also rated in:

B-cell acute lymphoblastic leukemiaDormant
CC
Indicative ·
47 / 100
View asset →
B-cell non-Hodgkin lymphomaDormant
CC
Indicative ·
47 / 100
View asset →
Relapsed/Refractory Acute Myeloid Leukemia, High-risk Myelodysplastic NeoplasmDormant
CC
Indicative ·
45 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →